Phase II study of erlotinib as first line chemotherapy in patients with lung adenocarcinoma with brain metastasis and EGFR mutations.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2018
Price : $35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Brain metastases; Lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2014 New trial record